Physician profile
Amy P Tees
NPI 1346229846
$246,893.82
in general payments reported to CMS, 2019-2025
38 companies · $43K in 2025
The $43K reported for 2025 was more than what 99% of Neuroscience (Registered Nurse) providers received nationally (typical 2025 total: $185).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64K · 2022: $50K · 2023: $33K · 2024: $57K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Honoraria: $26K · Consulting Fee: $22K · Travel and Lodging: $15K · Food and Beverage: $9,215 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,136.25 |
| Honoraria | $26,280.00 |
| Consulting Fee | $22,245.51 |
| Travel and Lodging | $14,572.44 |
| Food and Beverage | $9,214.72 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $104,715.25 | 2021-2025 | |
| Lundbeck LLC | $55,308.98 | 2021-2025 | Vyepti, Rexulti |
| Allergan, INC. | $32,047.75 | 2021-2022 | |
| Lilly USA, LLC | $17,744.62 | 2021-2025 | Emgality, Kisunla, Reyvow |
| Pfizer INC. | $16,896.83 | 2023-2025 | |
| Impel Pharmaceuticals INC. | $7,196.21 | 2022 | |
| Amgen INC. | $6,770.32 | 2021-2023 | Aimovig |
| Tonix Medicines, INC. | $1,264.99 | 2023-2025 | Zembrace Symtouch |
| Biodelivery Sciences International, INC. | $1,250.00 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $778.25 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $459.06 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $407.21 | 2021-2025 | Ajovy |
| Upsher-Smith Laboratories LLC | $332.87 | 2021-2023 | |
| Merz Pharmaceuticals, LLC | $191.11 | 2021-2025 | Xeomin |
| Neurocrine Biosciences, INC. | $190.97 | 2022-2024 | Ingrezza, Ongentys |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $183.35 | 2021-2024 | |
| Ucb, INC. | $151.08 | 2023-2024 | Rystiggo, Briviact, Fintepla |
| Biogen, INC. | $118.50 | 2021-2023 | Vumerity |
| Argenx US, INC. | $100.51 | 2023-2024 | Vyvgart Hytrulo |
| Medtronic, INC. | $90.80 | 2021-2022 | |
| Emd Serono, INC. | $84.34 | 2023-2025 | Mavenclad |
| Axsome Therapeutics, INC. | $82.55 | 2025 | Symbravo |
| Genzyme Corporation | $67.30 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $56.53 | 2023-2024 | Acthar |
| Supernus Pharmaceuticals, INC. | $55.57 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $54.76 | 2023-2024 | Ultomiris |
| Amneal Pharmaceuticals LLC | $47.87 | 2023-2024 | Lyvispah, Rytary |
| Scilex Pharmaceuticals INC. | $35.40 | 2023-2024 | Ztlido |
| Kyowa Kirin, INC. | $31.86 | 2023-2024 | Nourianz |
| Collegium Pharmaceutical, INC. | $26.67 | 2022 | |
| Almatica Pharma LLC | $24.16 | 2021 | |
| Sk Life Science, INC. | $23.72 | 2023 | |
| Celgene Corporation | $21.97 | 2023 | Zeposia |
| Sumitomo Pharma America, INC. | $20.51 | 2023 | Aptiom |
| Otsuka America Pharmaceutical, INC. | $17.76 | 2023 | Rexulti |
| Eisai INC. | $17.66 | 2023 | |
| Catalyst Pharmaceuticals, INC. | $13.33 | 2023 | Fycompa |
| Currax Pharmaceuticals LLC | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Tees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.